Breaking News, Financial News

Financial Report: AMRI 3Q10

Total contract revenue for the quarter was $42.9 million (+8%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI 3Q10

3Q Revenues:
$50.6 million (+6%)

3Q Loss: $9.9 million (earnings were $365,000 in 3Q09)

YTD Revenues:
$149.4 million (-2%)

YTD Loss: $13.8 million (earnings were $2.5 million YTD09)

Comments: Total contract revenue for the quarter was $42.9 million (+8%). Discovery Services revenue was flat at $11.9 million. Development/Small Scale Manufacturing revenue was $9.1 million (-6%). Large Scale Manufacturing revenue was $21.9 million (+20%). Royalties in the quarter were $7.7 million (-3%). Results in the quarter include the loss of $6.3 million from an unfavorable arbitration ruling related to Borregaard Industries’ cancellation of a purchase agreement.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters